StemCellPatents.com, an organization dedicated to the advancement of stem cell commercialization, has announced the launch of its newly re-designed free database covering US issued patents dealing with stem cells.
The website, www.stemcellpatents.com, provides comprehensive summaries and analysis of over 1200 patents hand-picked by experts in the field to be of relevance to stem cell commercialization and development.
“ The minefield of issued patents in the area of stem cell therapy is grossly underestimated by Industry. While the media has focused on the key WARF patents on embryonic stem cells, there are at least 1200 issued patents dealing with stem cells directly in one way or another, ” said Dr. Vladimir Bogin, a Principle in Cromos Pharma Services (www.cromospharma.com) and Member of the StemCellPatents.com advisory board. He continued, “ numerous companies are entering the area of stem cell therapeutics, however many of these companies do not know about the existence of these patents. Our efforts are targeted to allowing everyone to understand what is out there and what is not, with the hope of accelerating commercialization and, in turn, progress. ”
StemCellPatents.com launched a Beta Version of the site on November 10th, 2006. With industry input and guidance, the new website will continue to provide its subscribers and members with their increasingly popular weekly newsletter containing newly issued patents, as well as various new products and state-of-the-industry reports that will be added regularly and available on their website.
Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC